Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is thought to be an autoimmune condition. When you have CIDP, your immune system sees your nerves as foreign and attacks them. The attack ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

argenx has released preliminary results from the ADHERE trial, which tested VYVGART Hytrulo on adults with chronic inflammatory demyelinating polyneuropathy (CIDP), where the trial results were ...

The Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market was valued at USD 968 million in 2017 and is projected to reach USD 2,020.6 million by 2030. The total number of CIDP ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration ...